R. McCroskey

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

S. Jagannath, S. Lonial, A. Oriol, 2019, The Lancet. Haematology.

acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short‐course, high‐dose cytosine arabinoside, cisplatin, and etoposide

D. Mosher, C. D. Spencer, W. Longo, 1990, Cancer.

Antiphospholipid antibodies and adrenal hemorrhage

F. Mott, E. Williams, A. Phillips, 1991, American journal of hematology.

High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

F. Appelbaum, W. Nichols, S. Petersdorf, 1997, Bone Marrow Transplantation.

Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer

M. Socinski, R. Kurek, Michael Thomas, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

Jason J. Z. Liao, S. Jagannath, S. Lonial, 2018 .